Mitsubishi Tanabe Pharma Corporation announced today that Radicava® (generic name: edaravone, Japanese product name: RADICUT® inj.30mg) for an intravenous treatment for amyotrophic lateral sclerosis (ALS) has been launched in Australia on May 1 by a local licensee, Teva Pharma Australia Pty Ltd.

三菱田边制药公司今天宣布，由当地许可商特瓦制药澳大利亚有限公司于5月1日在澳大利亚推出用于肌萎缩侧索硬化症（ALS）的静脉注射治疗药物Radicava®（通用名：依达拉奉，日本产品名：RADICUT® 注射液30mg）。

Radicava® is a free radical scavenger developed by MTPC. It is assumed to have the effect of scavenging free radicals that increase in levels in the ALS pathology, protecting motor neurons from oxidative stress, and slowing the progression of muscle weakness and muscle atrophy.

Radicava® 是由MTPC开发的一种自由基清除剂。它被认为具有清除在ALS病理中水平升高的自由基、保护运动神经元免受氧化应激、减缓肌肉无力和肌肉萎缩进展的效果。

To maximize availability of Radicava® for patients, MTPC has been expanding the countries where the product could be available and developing oral formulation as a new route of administration. Edaravone was approved for the treatment of ALS in Japan, June 2015, followed by South Korea, U.S., Canada, Switzerland, Indonesia, Thailand, Malaysia, and Brazil is marketed..

为了使Radicava®对患者的最大可用性，MTPC一直在扩大该产品可能上市的国家，并开发口服制剂作为新的给药途径。依达拉奉于2015年6月在日本被批准用于治疗ALS，随后在韩国、美国、加拿大、瑞士、印度尼西亚、泰国、马来西亚和巴西上市。

MTPC will strive to provide Radicava® to patients fighting against ALS all over the world.

三菱制药将努力为全世界抗击ALS的患者提供Radicava®。

Contact:

联系人：

Mitsubishi Tanabe Pharma Corporation CEO Office PR Group

三菱田边制药公司首席执行官办公室公关组

+81-6-6205-5119

+81-6-6205-5119

Teva Pharma Australia Pty Ltd.

梯瓦制药澳大利亚有限公司

Teva Pharma Australia Pty Ltd. is a subsidiary of Teva Pharmaceutical Industries. Teva is a global pharmaceuticals leader focused on delivering high-quality medicines and innovative healthcare solutions to improve patient lives around the world.

Teva制药澳大利亚有限公司是Teva制药工业公司的子公司。Teva是一家全球领先的制药公司，专注于提供高质量的药物和创新的医疗保健解决方案，以改善世界各地患者的生活。

Source: pharma.co.jp

来源：pharma.co.jp